Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

Overview

Información sobre este estudio

The purpose of this study is to determine the effect of endogenous GLP-1 secretion on islet function in people with Typr 2 Diabetes Mellitus (T2DM).

GLP-1 is a hormone made by the body that promotes the production of insulin in response to eating. However, there is increasing evidence that this hormone might help support the body’s ability to produce insulin when diabetes develops. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria – Non-diabetic Subjects:

  • Weight-stable, non-diabetic subjects using the methods described above.

Exclusion Criteria - Non-diabetic Subjects: 

  • Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • HbA1c ≥ 6.5%
  • Use of glucose-lowering agents.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Subsequently, subjects will then undergo an Oral Glucose Tolerance Test to ensure that they have a fasting glucose ≤ 125mg/dl and a two-hour glucose ≤ 200mg/dl.

Inclusion Criteria – Diabetic Subjects:

  • Weight-stable, diabetic subjects treated with diet and lifestyle alone or with metformin monotherapy using the methods described above. 

Exclusion Criteria - Diabetic Subjects:

  • Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • Use of any glucose-lowering agent other than metformin.
  • 2 or more fasting glucose values > 250mg/dl on medication or after medication withdrawal.
  • Unwillingness or inability to withdraw medication for three weeks prior to, and for the duration of the study.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • The two groups will be matched for age, sex and weight.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Adrian Vella, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20520180

Mayo Clinic Footer